Study of T-PRED(TM) Compared to Pred Forte(R)
Information source: Bausch & Lomb Incorporated
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cataract
Intervention: T-PRED (Drug); T-PRED (Drug); Pred Forte (Drug); Pred Forte (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Bausch & Lomb Incorporated Official(s) and/or principal investigator(s):
Tim McNamara, PharmD, Study Director, Affiliation: ISTA Pharmaceuticals, Inc.
Summary
Study of T-PRED(TM) compared to Pred Forte(R)
Clinical Details
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
Primary outcome: Ratio of means aqueous humor prednisolone acetate concentrations
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 18 years of age
Exclusion Criteria:
- No active or adverse disease
Locations and Contacts
ISTA Pharmaceuticals, Inc., Irvine, California 92618, United States
Additional Information
Starting date: May 2008
Last updated: April 4, 2014
|
